Summit Therapeutics (SMMT) - 2025 Q4 - Annual Results

Financial Position - As of December 31, 2025, Summit Therapeutics Inc. reported a preliminary unaudited balance of cash, cash equivalents, and short-term investments of approximately $710 million[6] Regulatory Submissions - The company submitted a Biologics License Application to the U.S. FDA for ivonescimab in combination with chemotherapy for the treatment of patients with EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer[9] Clinical Collaborations - Summit Therapeutics announced a clinical trial collaboration with GSK to evaluate ivonescimab in combination with GSK's risvutatug rezetecan across multiple solid tumor settings, including small cell lung cancer[10]